Avoiding And Mitigating Delays In Outsourced Projects

This segment of the Outsourced Pharma Live event, “Small Molecule Outsourcing: Getting Timelines, Tech Transfer and Analytics Right,” examines the most common causes of timeline delays in outsourced small molecule development—such as tech transfer challenges, assay development gaps, lean SME resourcing, supply chain constraints, and quality events—and offers practical strategies like contractual detail, contingencies, on-site presence, schedule buffers, and understanding CDMO internal turnaround times, featuring panelists April Loui, SVP Quality and CMC Regulatory at ReCode Therapeutics, as well as Founder, CEO at Clarity Global Pharma, Natalie Farris, Executive CMC Consultant at Naltou Pharma CMC Consulting, LLC, and Thierry Bilbault, Co-founder and Principal at JT Biopharma Partners.